APA (7th ed.) Citation

Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., . . . Min, S. (2013). Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study. The Lancet (British edition), 382(9893), 700-708. https://doi.org/10.1016/S0140-6736(13)61221-0

Chicago Style (17th ed.) Citation

Cahn, Pedro, et al. "Dolutegravir Versus Raltegravir in Antiretroviral-experienced, Integrase-inhibitor-naive Adults with HIV: Week 48 Results from the Randomised, Double-blind, Non-inferiority SAILING Study." The Lancet (British Edition) 382, no. 9893 (2013): 700-708. https://doi.org/10.1016/S0140-6736(13)61221-0.

MLA (9th ed.) Citation

Cahn, Pedro, et al. "Dolutegravir Versus Raltegravir in Antiretroviral-experienced, Integrase-inhibitor-naive Adults with HIV: Week 48 Results from the Randomised, Double-blind, Non-inferiority SAILING Study." The Lancet (British Edition), vol. 382, no. 9893, 2013, pp. 700-708, https://doi.org/10.1016/S0140-6736(13)61221-0.